Clinical Trials
85 trialsSurgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
GCISAVE
University Hospital, Bordeaux
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
TASUC-Neo
Brown University
NeuroPrevPTSD
Centre Oscar Lambret
ALU
Hopital Foch
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Dana-Farber Cancer Institute
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
Mayo Clinic
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
Biomarker Identification for Bladder Cancer Patients
Ohio State University Comprehensive Cancer Center
A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers
Syneos Health
LCBH
University of Pittsburgh
Immune PDX
Duke University
Radiogenomics of Muscle Invasive Bladder Cancer
Cedars-Sinai Medical Center
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
CIRTiN-BC
University of Texas Southwestern Medical Center
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
University of California, Irvine
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
M.D. Anderson Cancer Center
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
University of Southern California
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
Hoosier Cancer Research Network
Bladder-Aid
Istituto Clinico Humanitas
LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer
Wake Forest University Health Sciences
RESECT
University Health Network, Toronto
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Sir Mortimer B. Davis - Jewish General Hospital
Adjuvant Radiation for High Risk Bladder Cancer
Emory University
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
Beijing Huanxing Cancer Hospital
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
University of Southern California
Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Baylor College of Medicine
Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy
Ottawa Hospital Research Institute
Cranberry
Hopital Foch
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
University of California, San Francisco
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
Fox Chase Cancer Center
Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection
University of Colorado, Denver
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
Peri-operative Aspirin Continuation Versus Discontinuation
Rabin Medical Center
N1
CureOne
MAGNOLIA
European Association of Urology Research Foundation
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester